Chris Howerton
Stock Analyst at Jefferies
(2.64)
# 2,033
Out of 5,240 analysts
66
Total ratings
44.23%
Success rate
20.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $6.39 | +17.37% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $39.84 | +213.76% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.46 | +23.84% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.63 | +145.40% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.09 | +378.47% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.21 | +28,990.91% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $19.01 | +3,687.48% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $3.03 | -83.50% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $29.68 | -66.31% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $41.03 | -2.51% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $30.76 | +98.31% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $232.27 | -61.25% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $32.45 | +103.39% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $8.91 | +146.91% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.11 | +1,791.89% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.54 | +3,954.55% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.09 | -4.93% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $8.03 | +7,122.91% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.99 | +2,915.08% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $58.30 | -72.56% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $105.55 | -74.42% | 1 | Jul 15, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $6.39
Upside: +17.37%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $39.84
Upside: +213.76%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.46
Upside: +23.84%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.63
Upside: +145.40%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.09
Upside: +378.47%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.21
Upside: +28,990.91%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $19.01
Upside: +3,687.48%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $3.03
Upside: -83.50%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $29.68
Upside: -66.31%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $41.03
Upside: -2.51%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $30.76
Upside: +98.31%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $232.27
Upside: -61.25%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $32.45
Upside: +103.39%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $8.91
Upside: +146.91%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.11
Upside: +1,791.89%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.54
Upside: +3,954.55%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.09
Upside: -4.93%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $8.03
Upside: +7,122.91%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.99
Upside: +2,915.08%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $58.30
Upside: -72.56%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $105.55
Upside: -74.42%